This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

UT-231B

United Therapeutics Corporation

Drug Names(s): UT-231B

Description: UT-231B is a small molecule glycobiology antiviral agent.

Deal Structure: In March 2000, Unither entered into a license agreement with Synergy Pharmaceuticals, a subsidiary of Callisto Pharmaceuticals, to obtain from Synergy the exclusive worldwide rights to certain patents relating to novel antiviral compounds. UT-231B is one of these agents.

Partners: Synergy Pharmaceuticals, Inc.


UT-231B News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug